1 2	Relationship between Polyunsaturated Fatty Acids and evidence from cohort and Mendelian randomization ar	Inflammation: nalyses		
3	Daisy C. P. Crick ^{1,2*} , Sarah Halligan ^{3,4} , George Davey Smith ^{1,2} , Go	olam M. Khandaker ^{1,2,5,6,7*}		
4	& Hannah J. Jones ^{1,2,5,7*}			
5				
6	1. MRC Integrative Epidemiology Unit, Population Health Sciences	s, Bristol Medical School,		
7	University of Bristol, Bristol, UK			
8	2. Population Health Sciences, Bristol Medical School, University	of Bristol, Bristol, UK		
9	3. Department of Psychology, University of Bath, Bath, UK			
10	4. Department of Psychiatry and Mental Health, University of Cap	e Town, South Africa		
11	5. NIHR Bristol Biomedical Research Centre, Bristol, UK			
12	6. Avon and Wiltshire Mental Health Partnership NHS Trust, Bristo	ы, UK		
13	7. Centre for Academic Mental Health, Population Health Science	es, Bristol Medical School,		
14	University of Bristol, Bristol, UK			
15	juint senior authors			
16				
17	Author for correspondence: Daisy Crick, University of Queensland	l, Institute of Molecular		
18	Bioscience. Email: <u>uqdcrick@uq.edu.au</u>			
19				

20 Word Count: Abstract: 190/200, Main body 3752/5000

^{*} Author for correspondence: Daisy Crick, University of Queensland, Institute of Medical Bioscience, St Lucia, 4072, Australia. Email: uqdcrick@uq.edu.au

22	Dietary polyunsaturated fatty acids (PUFAs) are thought to influence the risk of various
23	chronic diseases by modulating systemic inflammation. Omega-3 and omega-6 FAs are
24	thought to have anti- and pro-inflammatory roles, respectively, but it is unclear whether
25	these associations are causal. We tested associations of PUFAs with three blood-based
26	biomarkers of systemic inflammation, namely C-reactive protein (CRP), glycoprotein acetyls
27	(GlycA) and interleukin 6 (IL-6), in a population cohort (n=2748) and using Mendelian
28	randomization analysis (a genetic causal inference method). We provide consistent evidence
29	that omega-6 PUFAs increase GlycA levels, but omega-3 FAs do not lower levels of
30	inflammatory markers. Additionally, we found that a higher omega-6:omega-3 ratio
31	increases levels of all three inflammatory markers; CRP (mean difference=0.17; 95% CI=0.13,
32	0.20), GlycA (mean difference=0.16; 95% CI=0.13, 0.20) and IL-6 (mean differene=0.19; 95%
33	CI=0.15, 0.22) in the cohort analysis. Our findings suggest that future public health
34	messaging should encourage reducing the consumption of omega 6 FAs and maintaining a
35	healthy balance between omega 3 and omega 6 FAs, rather than focusing on omega-3 FA
36	supplementation. This is because dietary omega-3 supplementation alone is unlikely to help
37	reduce systemic inflammation or inflammation-related disease.
38	
39	Keywords: Systemic Inflammation; C-reactive Protein, Glycoprotein Acetyls, Interleukin 6,
40	Polyunsaturated fatty acids, Omega-3; Omega-6; Mendelian Randomization, ALSPAC.
41 42	
43	
44	
45	

48 **1. Introduction**

49 Non-communicable diseases (NCDs) are the main cause of global mortality, representing 71% of deaths worldwide². As such, their prevention remains a key challenge. Systemic low-50 grade inflammation, reflected by elevated concentrations of markers of inflammation such 51 52 as cytokines (e.g. interleukin-6 (IL-6)) and acute phase proteins (e.g. C-reactive protein (CRP)), has been implicated in the pathophysiology of many NCDs from cardiovascular 53 disease to depression³⁻¹². Therefore, inflammation appears a promising target for their 54 55 treatment and prevention. Polyunsaturated fatty acids (PUFAs), are proposed to influence levels of systemic 56 inflammation¹³. There are two main families of PUFAs which are essential for many 57

metabolic processes: Omega-3 $(n-3)^{14, 15}$; and Omega-6 $(n-6)^{15}$, along with eicosatetraenoic 58 acid and docosahexaenoic (DHA) acid (both n-3 PUFAs), and arachidonic acid (ARA; an n-6 59 PUFA) linked most clearly to various essential physiological processes. These processes 60 61 include maintaining cell membrane structural integrity, hormone synthesis, regulation of gene expression, and supporting brain and nervous system functioning¹⁶. Some PUFAs such 62 as ARA can come from both exogenous sources (such as meat and egg products) and 63 endogenous sources. This is where the PUFAs can be synthesized from their metabolomic 64 precursors: α-linolic acid (ALA; an n-3 PUFA) and linolic acid (LA: an n-6 PUFA), through 65 desaturation and elongation reactions¹⁷. In comparison, humans cannot synthesise LA or 66 ALA and therefore they must be acquired through dietary consumption¹⁸ such as vegetable 67 oils (for LA) and seed oils (ALA). 68

69

70	There is some evidence that N-3 PUFAs have anti-inflammatory effects and protect against
71	the severity/occurrence of inflammation-related conditions ^{19, 20} . For example, there are
72	suggestions that fatty fish consumption can reduce the probability of death from a heart
73	attack ^{21, 22} . This is attributed to n-3 PUFAs ability to alter the production of prostaglandins,
74	which subsequently reduce inflammation (measured by the reduced concentration of
75	circulating inflammatory biomarkers in the blood) ²³⁻²⁶ . However, clinical trials investigating
76	the effects of n-3 supplementation have yielded contradictory results ^{27 28} regarding its
77	effect on systemic inflammation. Dietary supplementation studies have reported that the
78	consumption of n-6 PUFAs, which are typically thought to be pro-inflammatory, did not
79	affect the concentration of inflammatory markers such as IL-6 or CRP $^{23, 29-31}$.
80	A meta-analysis of 14 clinical trials that included total 1,35,291 participants found that
81	omega-3 supplementation reduced the risk of major adverse cardiovascular event,
82	cardiovascular death and myocardial infarction ³² . In contrast, an RCT study investigating
83	dietary intake and mortality in 3114 men with angina, found that risk of cardiac death was
84	higher among individuals advised to eat oily fish or to take fish oil compared to those not
85	advised to do so. Additionally, RCTs investigating supplementation in patients to treat other
86	inflammation-related NCDs found similarly inconsistent results (e.g. ^{33 34}). However, these
87	studies did not directly test the effect of fatty acids on inflammation levels and the
88	inconsistent findings of the RCTs cast doubt on the posited immune modulatory effect sof n-
89	3 and n-6. Further, the contradictory results also raise questions of whether PUFAs causally
90	influence concentrations of biomarkers of inflammation or whether the observed
91	associations are the result of residual confounding.

92	Both n-3 and n-6 PUFAs are metabolized by the same enzymes and compete for
93	desaturation and elongation. This means it is plausible that n-6 PUFAs act as competitive
94	inhibitors of n-3 PUFAs and thus reduce the amount of end-product n-3 PUFAs that can be
95	synthesised ³⁵ . As a result, a lower concentration of n-3 PUFAs could reduce their anti-
96	inflammatory effects ³⁶⁻³⁸ . In contrast, a lower plasma n-6:n-3 ratio may result in higher
97	levels of end-product n-3 PUFAs which would subsequently lower concentrations of
98	inflammatory markers leading to beneficial effects on health outcomes ³⁹ . As such, further
99	research to understand the importance of the n-6:n-3 ratio on levels of inflammation and its
100	impact on the occurrence of NCDs is of public health concern.
101	We examined whether circulating levels of PUFAs are associated with systemic biomarkers
102	of inflammation using (1) data from a population-based prospective birth cohort and (2)
103	two-sample Mendelian randomization (MR), a causal inference method that uses genetic
104	variants as proxies to examine whether the association between a risk factor and a disease
105	outcome is likely to be causal or result of residual confounding or reverse causaltion ⁴⁰ .
106	We investigated the effects on inflammatory markers of specific n-3 and n-6 PUFAs which
107	play a role in key metabolic processes. These are the long-chain n-3 PUFA DHA and the
108	short-chain n-6 PUFA LA which appear at opposite ends of the biosynthesis pathways (see
109	figure 1; adapted from Videla et al. ¹). In addition, for a greater interrogation of the PUFA-
110	inflammation relationship, we used measures of total n-3 PUFAs, total n-6 PUFAs and the
111	ratio of total n-6 PUFAs:total n-3 PUFAs (referred hereafter as the total n-6:n-3 ratio) as
112	exposures. As outcomes we used three biomarkers for systemic inflammation, namely CRP,
113	IL-6, and Glycoprotein Acetyls or GlycA (a novel composite biomarker of inflammatory acute
114	phase proteins ^{41,42}).

115 **2. Results**

- 116 2.1 Findings from Population-based Cohort Analyses
- 117 Table 1 presents the median/range for PUFA levels (DHA, LA, total n-3 PUFAs and total n-6
- 118 PUFAs) and inflammatory biomarker levels (IL-6, CRP and GlycA) from participants of the
- Avon Longitudinal Study of Parents and Children (ALSPAC) birth cohort at age 24y. There
- 120 was no difference between the complete-case and imputed results (eTable 15) and
- distributions of observed and imputed characteristics are presented in supplementary
- 122 eTable 16. The results of the below associations are presented in eTable17 and eTable 18.
- 123 2.1.1 Associations of DHA and LA with inflammatory markers
- Both DHA and LA were associated with higher CRP and GlycA levels, but lower IL-6 levels at
- 125 24y after adjusting for potential confounders relating to sex, substance use, social economic
- 126 position, and maternal pregnancy health (Figure 2).
- 127 2.1.2 Associations of total n-3 and n-6 PUFAs with inflammatory markers
- 128 Total n-3 and n-6 PUFAs were associated with higher GlycA levels, but lower IL-6 levels at
- 129 24y after adjusting for potential confounders. Total n-6 was associated with higher CRP
- 130 levels but there was no strong evidence of association between total n-3 PUFAs and CRP
- 131 (Figure 2).
- 132 2.1.3 Associations between total n-6:n-3 ratio and inflammatory markers
- 133 The total n-6:n-3 ratio was associated with higher levels of all three inflammatory markers
- 134 (CRP, GlycA and IL-6) at age 24y after adjusting for potential confounders (Figure 2).
- 135 2.1.4 Sex Specific Associations between PUFAs and Inflammatory Markers

136 In sex-stratified analyses, the n-6:n-3 ratio was associated with higher levels of all three

137 inflammatory markers in both sexes (Figure 3). PUFAs were also associated with higher

138 GlycA in males and females. The effects of all PUFAs on CRP and IL-6 levels attenuated to

- the null in males. In females, PUFAs were associated with higher CRP but lower IL-6 levels,
- 140 which mirrored findings from the whole cohort analysis.
- 141 2.2 Results for Mendelian Randomization Analyses
- 142 We used two-sample MR to assess evidence for causality using publicly available summary-
- 143 level data from European population GWAS of the PUFAs⁴³, GlycA⁴⁴, CRP⁴⁵ and IL-6⁴⁶. See
- 144 eMethods for further information.
- 145 Tests investigating instrument validity, described in the methods section, indicated that
- instruments were unlikely to be subject to weak instrument bias (see eResults).
- 147 2.2.1. Potential causal effect of DHA on inflammatory markers
- 148 We observed no strong evidence of effect of DHA levels on CRP (IVW estimate: 0.03; 95%
- 149 CI: -0.01, 0.09), GlycA (IVW estimate: 0.01; 95% CI: -0.06, 0.07) or IL-6 (IVW estimate: 0.07;
- 150 95% CI: -0.20, 0.07). These results were largely consistent across sensitivity analyses using
- 151 MR methods that make different assumptions about instrument validity (MR-egger,
- 152 weighted median and weighted mode) (Figure 4).
- 153 2.2.2. Potential causal effect of LA on inflammatory markers
- 154 We observed no strong evidence of effect of LA levels on CRP (IVW estimate: -0.10; -0.10,
- 155 0.09) or IL-6 (IVW estimate: 0.02; -0.05, 0.08). We observed estimates suggesting that higher
- LA levels cause higher GlycA levels (IVW estimate: 0.25; 0.15, 0.35). Other than in the
- analysis investigating the effect of LA levels on CRP, results were consistent across MR
- 158 sensitivity methods (Figure 4).

159 2.2.3. Potential causal effect of total n-3 PUFA levels on inflammatory markers

160 Higher total n-3 PUFA levels were associated with higher CRP (IVW estimate: 0.09; 0.03,

161 0.16) and GlycA (IVW estimate: 0.12; 0.04, 0.21) levels. We observed no effect of total n-3

- 162 PUFA levels on IL-6 (IVW estimate: -0.04; -0.09, 0.02). Results attenuated to the null in all
- 163 MR sensitivity analyses of total n-3 PUFA levels and GlycA (Figure 4).
- 164 2.2.4. Potential causal effect of total n-6 PUFA levels on inflammatory markers
- 165 We observed no strong evidence of effect of total n-6 PUFA levels on CRP (IVW estimate:
- 166 0.04, -0.05, 0.13) or IL-6 (IVW estimate: -0.08; -0.03, 0.04). We did observe estimates that
- suggest that higher n-6 PUFA levels cause higher GlycA levels (IVW estimate: 0.25; 0.16,
- 168 0.34) with estimates consistent in sensitivity analyses with the exception of the weighted
- 169 mode analysis (Figure 4).

170

- 171 2.3 Evidence of pleiotropy and heterogeneity
- 172 MR Egger intercepts and tests for heterogeneity between the SNP effect estimates are

173 presented in eTable 19. There was no strong evidence of pleiotropic effect as detected by

174 the MR-Egger intercept for the association between PUFA levels and any biomarker with the

- exception of the association between total n-3 levels and GlycA. Findings were fairly
- 176 consistent with results using the MR-PRESSO test for pleiotropy (eTable20). There was
- strong evidence of heterogeneity in all analyses apart from in analyses of total n-3 and LA
- 178 levels and IL-6.

179

180 2.4 Findings on the potential impact of methodological biases in MR results

181 MR-Lap ⁴⁷was used to assess potential biases in observed effect estimates due to sample

182 overlap between the fatty acid, CRP and GlycA GWAS. Results suggested that the majority of

analyses were largely unaffected by winner's curse and weak instrument biases introduced
through sample overlap. The corrected effect differed from the observed effect only for
analysis investigating the effect of total n-6 PUFAs on GlycA and CRP levels. In both
instances, the observed effect estimate was in the same direction as the corrected estimate
and the confidence intervals did not cross the null but were wider. See eResults for further
information.

189

190 2.5 Results from MR Analysis Focusing on Specific Genes

191 The FADS gene cluster and ELOVL2 gene encode key desaturase and elongase enzymes

respectively and are involved in the n-3 and n-6 fatty acid biosynthesis pathways. Therefore,

193 we conducted a complementary and mechanistically informative MR analysis by using only

194 genetic instruments from within or close to the FADS gene cluster (FADS1, FADS2 and

195 *FADS3*) and *ELOVL2* gene with the aim of reducing the impact of other pleiotropic pathways.

196 MR analyses using SNPs from the FADS gene region showed that DHA increases CRP levels

197 (IVW estimate: =0.04; 95% CI=0.01, 0.07), but LA decreases CRP levels (IVW estimate: =-

198 0.14; -0.20, -0.07). FADS instrumented DHA and LA had no effect on GlycA and (where

199 testable) IL-6. There was no evidence of a causal effect of any SNPs from the *ELOVL2* gene

200 on GlycA, CRP, or IL-6. See eResults for further information.

201

202 2.6 Results from analyses exploring heterogeneity of MR instruments

203 Given that evidence of associations between the PUFAs and GlycA were largely consistent

across cohort and MR analyses, we used MR-Clust ⁴⁸to investigate whether there were

205 distinct clusters of SNPs effects driving the heterogeneity observed in the MR analysis with

206 GlycA levels as the outcome. In the analysis using genetic instruments for LA, total n-3 207 PUFAs and total n-6 PUFAs, all clusters were positively associated with GlycA which is 208 consistent with the main results. However, for DHA, there were two SNP clusters showing a 209 positive association with GlycA and one cluster showing a negative association with GlycA 210 levels. This could explain the observed null results between DHA and GlycA found in the 211 main analysis. See eResults, eTable 26, and eFigures 3-6 for further information. 212 We obtained functional annotations of the genomic loci associated for all identified clusters 213 from FUMAGWAS (https://fuma.ctglab.nl) and investigated in which tissues the genes were 214 up- or down-regulated (eFigures 7-10). Overall, most differentially expressed genes were 215 expressed in the liver. For the association between DHA and GlycA, tissues with most 216 differentially expressed genes were: liver (cluster 1), breast (cluster 2) and kidneys (cluster 217 5). For the association between LA and GlycA, tissues with most differentially expressed 218 genes were: liver (clusters 1 and 2) and kidneys (cluster 4). For the association between total 219 omega-3 and GlycA, most differentially expressed genes in both clusters 2 and 6 were in 220 liver. Finally, for the association between total omega-6 and GlycA, most differentially 221 expressed genes were in kidneys (cluster 1) and liver (cluster 4).

222

223 2.7 Multivariable MR investigating the direct effects of total omega-3 and total omega-6 on
 224 inflammatory markers

We conducted a Multivariable Mendelian Randomization (MVMR) analysis to estimate the individual direct causal effects of total n-3 and n-6 PUFAs on the biomarkers of inflammation independently of each other. We observed a positive direct effect of total n-6 PUFA levels on both GlycA (IVW estimate: 0.33; 0.19, 0.47) and CRP levels (IVW estimate: 0.20; 0.01,

0.39), but not IL-6 levels (IVW estimate: 0.17; -0.17, 0.50), after controlling for the effect of
n-3 PUFAs. There was no direct effect of total n-3 PUFA levels on GlycA (IVW estimate: 0.06;
-0.05, 0.16), CRP (IVW estimate:0.03; -0.06, 0.12) or IL-6 (IVW estimate: -0.18; -0.49, 0.14)
levels after controlling for the effect of n-6 PUFAs. This suggests that the effect of total n-3
PUFAs on CRP levels found in the univariable MR analysis are not independent of the effect
of n-6, and may be a result of pleiotropy (Figure 5). See eResults for further information on
MVMR analysis.

236

237 **3. Discussion**

238 By combining complementary cohort and genetic analyses, we provide greater insight into 239 the relationships between dietary PUFAs and systemic inflammatory markers. Our analyses 240 of population cohort data show a consistent effect of the n-6:n-3 ratio on higher levels of all 241 three inflammatory markers in the total sample and in males and females separately. 242 However, the picture appears to be more complex when we consider total or individual FA 243 levels. For instance, total n-3 FAs levels which are thought to be anti-inflammatory are not 244 associated with CRP levels. Similarly, n-6 (thought to be pro-inflammatory) as well as n-3 245 PUFAs are associated with an increase in GlycA levels, but a decrease in IL-6. 246 Subsequent genetic analyses shed light into the complex nature of these associations 247 including the important issue of causality. First, MR results showing a potentially causal 248 effect of total n-3 PUFAs on higher circulating CRP and GlycA levels contrast the presumed 249 anti-inflammatory effect of n-3 PUFAs, and argues against the widespread use of n-3 250 supplementation aimed at improving health by reducing inflammation-related disease risk. 251 Second, our MR results confirm that total n-6 and LA increase GlycA (a pro-inflammatory

252 marker), suggesting a pro-inflammatory effects of these FAs. The importance of n-6 FAs with 253 regards to modulating inflammation, rather than n-3 FAs, was also highlighted by our 254 MVMR analysis which provided evidence for a direct causal effect of total n-6 FAs increasing 255 CRP and GlycA levels after accounting for the effect of total n-3 PUFA levels. In contrast, no 256 independent effect on inflammatory marker levels was observed for total n-3 FAs. 257 Results from our further MR analyses using genetic variants within/nearby a key gene 258 involved in fatty acid metabolism (FADS gene cluster), indicate that several PUFA-259 inflammatory marker associations may result from pleiotropic effects of FA-related genetic 260 variants, rather than the effect of FA biosynthesis. These include the effect of LA on GlycA, 261 effect of total n-3 PUFAs on CRP and GlycA, and effect of total n-6 PUFAs on GlycA. Our 262 approach of investigating the effect of specific genes within the PUFA biosynthesis pathway is similar to recent work by Haycock *et al*⁴⁹ who investigated the effect of *FAD1* and *FAD2* 263 264 genes on cancer. They reported that genetically elevated PUFA desaturase activity, 265 instrumented by one SNP (rs174546), was associated with higher risk of colorectal and lung 266 cancer. Future research should investigate whether desaturase activity promotes certain 267 cancer risk through increased inflammation. 268 N-3 and n-6 PUFAs act as competitive inhibitors disrupting each other's desaturation and elongation³⁶. Therefore, a greater concentration of n-6 PUFAs would result in a fewer 269 270 number of endpoint n-3 PUFAs being synthesized. This could be one explanation for the lack 271 of an anti-inflammatory effect of n-3 PUFAs in our work. This may also explain our finding of 272 positive associations between total n-6:n-3 PUFA levels and all three inflammatory marker 273 levels in our cohort analysis.

274 A higher n-6:n-3 ratio is thought to promote the pathogenesis of inflammation-related NCDs such as cardiovascular disease, arthritis and asthma⁵⁰, and a meta-analysis of RCTs found 275 that supplementation of a low n-6:n-3 PUFA ratio inducing diet decreased concentrations of 276 inflammatory markers such as tumor necrosis factor- α and IL-6⁵¹. Therefore, it is possible 277 278 that n-6:n-3 PUFAs ratio is more important than concentrations of individual PUFAs with 279 regards to the risk of inflammation-related NCDs. We were unable to conduct MR for n6:n3 280 ratio because of the lack of GWAS for this measure. This should be prioritized when such 281 data becomes available in future.

282 We investigated the association between PUFAs and levels of CRP, IL-6 and GlycA, using two 283 different methods and used sensitivity analyses to address potential biases that arise in 284 epidemiological research. Despite this, we recognize several limitations. We used cross-285 sectional analyses which means it is difficult to infer causality and we cannot determine the 286 temporal relationship between the exposure and the outcome or the directionality of this 287 relationship. Additionally, the cohort analysis was limited to only participants reported as 288 White and the GWAS used were only conducted in individuals of European descent. This 289 limits the generalizability of the results to other populations. However, the cohort analysis 290 provides useful context and provides evidence for associations between PUFA levels and 291 biomarkers of inflammation, including GlycA, which is novel.

292 DHA and LA appear at the different ends of FA biosynthesis pathways (n-3 DHA is an 293 endogenous product of a chain of desaturation and elongation reactions, while LA is a pre-294 cursor to these reactions on the n-6 PUFA pathway). This means that a comparison between 295 the effects of these specific n-3 and n-6 PUFAs is difficult. Future large-scale, well-powered

GWAS of specific PUFAs across the biosynthesis pathway at comparable stages are neededto help better understand this relationship.

298	There was sample overlap between the exposure and outcome GWAS data used for MR
299	analyses, which may lead to overfitting. However, recent research suggests that the bias
300	incurred through sample overlap is less substantial compared to biases produced by weak
301	instruments or winner's curse ⁴⁷ . These biases are unlikely to be issues for our MR analyses
302	as confirmed by various sensitivity analyses exploring these concerns specifically.
303	Heterogeneity in the two-sample MR analyses may have biased causal estimates towards
304	the null. Although we did investigate the outcome of the heterogeneity within the GlycA
305	analyses using MR-Clust, no clusters were specifically related to inflammation-related
306	processes.
307	Lastly, although the FADS gene cluster encodes enzymes fundamental to PUFA biosynthesis
308	suggesting that IVs within this region are more likely to satisfy MR assumptions, FADS
309	variants have been shown to be highly pleiotropic 52 and do not differentiate n-3 or n-6
310	effects. As such, our gene based analyses may capture pathways to inflammation through
311	factors other than PUFAs, thus violating the exclusion-restriction assumption ⁴⁰ .

Given the popular use of n-3 PUFAs as supplements to reduce the occurrence of

inflammation-related NCDs^{27, 53, 54}, our results are of public health importance. Importantly,
our MR results suggest that n-6 PUFAs increase levels of CRP and GlycA when controlling for
n-3 PUFAs and that a higher total n-6:n-3 ratio increases levels of all three biomarkers. As
such, instead of focusing solely on n-3 PUFA consumption, public health messaging should
move towards encouraging a lower total n-6 PUFA consumption and to achieve a healthy
balance between n-3 and n-6 to help reduce the occurrence of inflammation-related NCDs.

319 However, as there is evidence that suggests that n-3 PUFA consumption is also beneficial to health because of its hypotriglyceridaemic effects⁵⁵, a better understanding of the interplay 320 321 between n-6 and n-3 effects, as well as potential beneficial non-inflammation related 322 effects, is needed before considering implementing n-6 focussed changes to policy. 323 4. Conclusion 324 Our MR results suggest that higher LA and total n-6 PUFA levels increase GlycA, but not CRP 325 or IL-6 levels. Our MR results also suggest that higher total n-3 PUFA levels increase CRP and 326 GlycA levels, but do not increase IL-6 levels. We provide consistent evidence for positive 327 associations between total n-6:n-3 ratio and levels of CRP, GlycA and IL-6, indicating that the 328 ratio of total n-6:n-3 PUFAs may be more important with regards to systemic inflammation 329 than individuals PUFAs. However, these results came from cross-sectional analyses of cohort 330 data and we were unable to examine evidence of causality for the effects of total n-6:n-3 331 ratio using MR due to lack of GWAS data for total n-6:n-3 ratio. Nevertheless, our findings 332 do not support a strong anti-inflammatory effect of n-3 PUFAs from both cohort and MR 333 analyses. This finding requires further investigation given that n-3 PUFA supplementation 334 widely used to reduce inflammation and risk of inflammation-related NCDs.

335 **5. Methods**

336 5.1 Cohort Analysis

337 5.1.1 Dataset and sample

The Avon Longitudinal Study of Parents and Children (ALSPAC) birth cohort recruited pregnant women resident in Avon, UK with expected dates of delivery between 1st April 1991 and 31st December 1992 ⁵⁶⁻⁵⁸. There were 14, 203 unique mothers initially enrolled in the study and the initial number of pregnancies enrolled was 14,541 and 13,988 children

342 were alive at 1 year of age. When the oldest children were approximately 7 years of age, the 343 initial sample was bolstered with eligible cases who did not originally join the study. The 344 total sample size for analyses using any data collected after the age of seven is therefore, 345 14,833 unique mothers and 15,447 pregnancies which resulted in 15,658 foetuses. Of these, 346 14,901 were alive at 1 year of age. The offspring, their mothers and the mother's partners 347 are regularly followed up. Additional information on ALSPAC is presented in the supplement 348 eMethods. For eligibility criteria see the study flowchart (eFigure 1) in the supplement. 349 For this study, ALSPAC participants were included if they had outcome (CRP, IL-6 and GlycA 350 levels) and exposure (DHA, LA, total n-3 and total n-6) data at 24y. We excluded non-white 351 participants (2% of study population) and this exclusion is unlikely to make any difference to the results due to low numbers of non-white individuals in the dataset. This gave a total of 352 353 2748 individuals (36.10% males) eligible for our analysis. 354 5.1.2 PUFAs and inflammatory marker assays 355 Participants fasted overnight, or >6 hours if being seen in the afternoon, before attending 356 the clinic for blood sampling at 24 years old. Blood samples were centrifuged immediately 357 to isolate plasma and stored at -80 °C. There were no freeze-thaw cycles during storage. 358 Total n-3, n-6, DHA and LA PUFA levels and plasma GlycA levels were measured using a high-359 throughput proton (1H) Nuclear Magnetic Resonance (NMR) metabolomics platform (Nightingale, UK)^{42, 59}. We also created a n-6:n-3 ratio (total n-6 PUFAs divided by total n-3 360 361 PUFAs). HsCRP was measured by automated particle-enhanced immunoturbidimetric assay (Roche UK, UK). IL-6 was measured by enzyme-linked immunosorbent assay (OLINK, UK). 362 363 The samples were collected when the participansts were 24 years old. Full dtails regarding

sample processing, NMR analysis, and data processing have been provided elsewhere⁶⁰⁻⁶².

365	GlycA levels ranged from 0.84 to 2.25 mmol/L, and IL-6 levels ranged from 1.82 to 10.60
366	Normalized Protein eXpression (NPX) Log2 scale. CRP had detection limits of 0.15-80mg/L
367	and measures outside this were removed. CRP levels ranged from 0.15 to 70.05 mg/L.
368	5.1.3 Assessment of Covariates
369	We used maternal self-reported highest educational qualification and highest occupation of
370	either parent (measures of social economic position (SEP)), maternal and paternal smoking
371	pattern during pregnancy (measures of pregnancy health), participants' sex, and
372	participants' smoking status and drinking status at age 24 as covariates. A detailed
373	description of how these variables were collected/coded is provided in the supplement
374	eMethods.
375	5.1.4 Statistical analysis
376	Multivariable linear regression analyses were used to examine the cross-sectional
377	associations of PUFA levels with GlycA ,CRP and IL-6 levels at age 24y. Regression models
378	were adjusted for potential confounders. CRP and IL-6 levels were not normally distributed
379	and were log-transformed. To help with the interpretation of results, we z-transformed both
380	exposure and outcome data, and so the effect estimates represent the increase in outcome
381	in standard deviation (SD) per SD increase in exposure. Primary analyses used the whole
382	sample, and in secondary analyses we stratified by sex.
383	We used multiple imputation (MI) to impute missing exposure, outcome and covariate data
384	in the eligible sample (N=2748), described in detail in the supplement eMethods.
385	
386	5.2 Two-sample Mendelian Randomisation Analysis

387 5.2.1 Study design and data sources

388 Genome-wide significant single nucleotide polymorphisms (SNPs) ($P < 5.0 \times 10-8$) were selected as IVs for MR analyses. The SNPs were harmonized, aligning the genetic association 389 390 for exposure and outcome on the effect allele using the effect allele frequency (see 391 eMethods for details). Following harmonisation of the PUFA SNP instrument with the 392 corresponding outcome data (inflammatory biomarker), palindromic SNPs were removed 393 and the remaining SNPs underwent LD clumping. Steiger filtering was then applied, meaning 394 SNPs were removed if they explained more variance in the outcome than in the exposure. 395 The number of SNPs removed due to being palindromic, in linkage disequilibrium (LD) or as 396 a result of Steiger filtering for each analysis is reported in eTable 1. There were 46-58 SNPs 397 available to investigate the effect of PUFAs on GlycA levels, 17-39 SNPs available to 398 investigate the effect of PUFAs on CRP levels and 11-44 SNPs available to investigate the 399 effect of PUFAs on IL-6 levels. Harmonized SNP information for each relationship are 400 presented in eTables 2-13. See eMethods for further details on instrument selection. 401 5.2.2 Statistical analysis

For MR, the inverse variance weighted (IVW)⁶³ method was used as a primary analysis to
calculate effect estimates. MR-Egger, weighted median, and weighted mode methods were
used as sensitivity analyses as these methods make different assumptions about instrument
validity. Findings were considered robust if results were consistent across primary and
sensitivity analyses.

407 We report *F*-statistics for IVs, as a measure of instrument strength. Presence of

408 heterogeneity between the SNP effect estimates was assessed using Cochran's Q test in the

409 IVW analysis and the Rucker's Q test in the MR-Egger analyses. We used the MR-Egger

410 intercept and MR Pleiotropy Residual Sum and Outlier global test (MR-PRESSO) to

- 411 investigate the presence of pleiotropy. See eTable 14 for a description of MR methods and
 412 sensitivity analyses used⁶⁴.
- 413 5.2.3 MR-Lap analysis to investigate bias from sample overlap, weak instrument and

414 Winner's Curse

The fatty acid GWAS, the CRP GWAS and GlycA GWAS were conducted using UKB data. This

sample overlap may modify biases caused by the use of weak instruments and winner's

417 curse. To overcome this, the MR-Lap method was used to assess potential bias in observed

418 effect estimates due to sample overlap, winner's curse, or weak instruments⁴⁷. Greater

- 419 detail of MR-Lap method is provided in eMethods.
- 420 5.2.4 Additional MR analysis focusing on specific PUFA genes
- 421 MR was conducted using genetic instruments (SNPs) from within or close to (+/-500 kb) the

422 FADS gene cluster (FADS1, FADS2 and FADS3; chromosome 11: 6125602452–6126592523)

423 and ELOVL2 gene (chromosome 6: 1029802992–1120442624) from the DHA GWAS and the

424 LA GWAS. SNPs were selected and harmonised using the same method as in the primary

425 analysis and details are presented in the eMethods. The number of SNPs available for each

426 analysis is presented in eMethods.

427 5.2.5 MR-Clust analysis to explore heterogeneity in MR instruments

- 428 SNPs can influence the outcome in distinct ways (e.g., via distinct biological mechanisms)⁴⁸.
- 429 This can lead to high levels of heterogeneity between individual SNP-outcome/SNP-
- 430 exposure causal estimates within an instrument. Therefore, we decided to use MR-Clust⁴⁸ to
- 431 investigate whether individual causal estimates fell into distinct clusters based on effect
- 432 magnitude. We used this method when evidence of association was consistent between

- 433 cohort and MR analyses but there was strong evidence of heterogeneity in the latter.
- 434 Functional annotations of the genomic loci associated with identified clusters was obtained
- 435 from FUMAGWAS (<u>https://fuma.ctglab.nl</u>). See further details in eMethods.
- 436 5.2.6 Multivariable Mendelian Randomisation analysis
- 437 MVMR⁶⁵ is an extension of MR that estimates the *direct effect* of each exposure on the
- 438 outcome, rather than the overall total effect of the exposures (eFigure 2 of the supplement).
- 439 We conducted a MVMR analysis to estimate the individual direct causal effects of total n-3
- and n-6 PUFAs on the biomarkers of inflammation independently of each other. See further
- 441 details in eMethods.
- 442 5.3 Software
- 443 Cohort analyses were performed using STATA version 17.0. All other analyses were
- 444 performed in R Software version 4.1.0.
- 445
- 446
- 447
- 448
- 449
- 450
- 451
- 452
- 453
- 454
- 455
- 456
- 457

458 References

459 Videla LA, Hernandez-Rodas MC, Metherel AH, Valenzuela R. Influence of the nutritional 1. 460 status and oxidative stress in the desaturation and elongation of n-3 and n-6 polyunsaturated fatty 461 acids: Impact on non-alcoholic fatty liver disease. Prostaglandins, Leukotrienes and Essential Fatty 462 Acids 2022; 181: 102441. 463 2. Collaborators GRF. Global burden of 87 risk factors in 204 countries and territories, 1990-464 2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet 2020; **396**: 1223-49. 465 3. Calder PC, Albers R, Antoine JM, et al. Inflammatory Disease Processes and Interactions with 466 Nutrition. British Journal of Nutrition 2009; 101: 1-45. 467 Calabrò P, Golia E, Yeh ET. CRP and the risk of atherosclerotic events. Seminars in 4. 468 Immunopathology; 2009: Springer; 2009. p. 79-94. 469 5. Calabro P, Golia E, TH Yeh E. Role of C-reactive protein in acute myocardial infarction and 470 stroke: possible therapeutic approaches. Current Pharmaceutical Biotechnology 2012; 13: 4-16. 471 6. Sabaawy HE, Ryan BM, Khiabanian H, Pine SR. JAK/STAT of all trades: linking inflammation 472 with cancer development, tumor progression and therapy resistance. Carcinogenesis 2021; 42: 1411-473 9. 474 7. Rothwell PM, Wilson M, Price JF, Belch JF, Meade TW, Mehta Z. Effect of daily aspirin on risk 475 of cancer metastasis: a study of incident cancers during randomised controlled trials. The Lancet 476 2012; 379: 1591-601. 477 8. Rothwell PM, Fowkes FGR, Belch JF, Ogawa H, Warlow CP, Meade TW. Effect of daily aspirin 478 on long-term risk of death due to cancer: analysis of individual patient data from randomised trials. 479 The Lancet 2011; 377: 31-41. 480 Connelly MA, Otvos JD, Shalaurova I, Playford MP, Mehta NN. GlycA, a novel biomarker of 9. 481 systemic inflammation and cardiovascular disease risk. Journal of Translational Medicine 2017; 15: 482 219. 483 10. Dowlati Y, Herrmann N, Swardfager W, et al. A meta-analysis of cytokines in major 484 depression. Biol Psychiatry 2010; 67: 446-57. 485 11. Fries GR, Walss-Bass C, Bauer ME, Teixeira AL. Revisiting inflammation in bipolar disorder. 486 Pharmacology Biochemistry and Behavior 2019; 177: 12-9. 487 12. Oliveira J, Oliveira-Maia A, Tamouza R, Brown A, Leboyer M. Infectious and immunogenetic 488 factors in bipolar disorder. Acta Psychiatrica Scandinavica 2017; 136: 409-23. 489 13. Currenti W, Godos J, Alanazi AM, et al. Dietary Fats and Cardio-Metabolic Outcomes in a 490 Cohort of Italian Adults. Nutrients 2022; 14: 4294. 491 El-Badry AM, Graf R, Clavien PA. Omega 3 - Omega 6: What is right for the liver? J Hepatol 14. 492 2007; 47: 718-25. 493 15. Miles EA, Childs CE, Calder PC. Long-Chain Polyunsaturated Fatty Acids (LCPUFAs) and the 494 Developing Immune System: A Narrative Review. Nutrients 2021; 13. 495 16. Sampath H, Ntambi JM. Polyunsaturated fatty acid regulation of gene expression. Nutr Rev 496 2004; 62: 333-9. 497 17. Sokoła-Wysoczańska E, Wysoczański T, Wagner J, et al. Polyunsaturated Fatty Acids and 498 Their Potential Therapeutic Role in Cardiovascular System Disorders-A Review. Nutrients 2018; 10. 499 Burns-Whitmore B, Froyen E, Heskey C, Parker T, San Pablo G. Alpha-Linolenic and Linoleic 18. 500 Fatty Acids in the Vegan Diet: Do They Require Dietary Reference Intake/Adequate Intake Special 501 Consideration? Nutrients 2019; 11. 502 19. Hodge L, Salome CM, Peat JK, Haby MM, Xuan W, Woolcock AJ. Consumption of oily fish and 503 childhood asthma risk. Medical Journal of Australia 1996; 164: 137-40. 504 20. Calder PC. n-3 polyunsaturated fatty acids, inflammation, and inflammatory diseases. Am J 505 Clin Nutr 2006; 83: 1505s-19s. 506 21. Chaddha A, Eagle KA. Omega-3 fatty acids and heart health. *Circulation* 2015; **132**: e350-e2.

507 22. Kris-Etherton PM, Fleming JA. Emerging nutrition science on fatty acids and cardiovascular 508 disease: nutritionists' perspectives. *Adv Nutr* 2015; **6**: 326s-37s.

509 23. Pischon T, Hankinson SE, Hotamisligil GKS, Rifai N, Willett WC, Rimm EB. Habitual Dietary
510 Intake of n-3 and n-6 Fatty Acids in Relation to Inflammatory Markers Among US Men and Women.
511 *Circulation* 2003; **108**: 155-60.

512 24. Lopez-Garcia E, Schulze MB, Meigs JB, et al. Consumption of trans fatty acids is related to
513 plasma biomarkers of inflammation and endothelial dysfunction. *The Journal of Nutrition* 2005; **135**:
514 562-6.

515 25. Kiecolt-Glaser JK, Belury MA, Andridge R, Malarkey WB, Glaser R. Omega-3 supplementation 516 lowers inflammation and anxiety in medical students: a randomized controlled trial. *Brain, Behavior,* 517 *and Immunity* 2011; **25**: 1725-34.

518 26. Hu FB, Manson JE. Omega-3 Fatty Acids and Secondary Prevention of Cardiovascular
519 Disease—Is It Just a Fish Tale?: Comment on "Efficacy of Omega-3 Fatty Acid Supplements
520 (Eicosapentaenoic Acid and Docosahexaenoic Acid) in the Secondary Prevention of Cardiovascular
521 Disease". Archives of Internal Medicine 2012; **172**: 694-6.

522 27. Goldberg RJ, Katz J. A meta-analysis of the analgesic effects of omega-3 polyunsaturated 523 fatty acid supplementation for inflammatory joint pain. *Pain* 2007; **129**: 210-23.

524 28. MacLean CH, Mojica WA, Morton SC, et al. Effects of omega-3 fatty acids on lipids and 525 glycemic control in type II diabetes and the metabolic syndrome and on inflammatory bowel disease, 526 rheumatoid arthritis, renal disease, systemic lupus erythematosus, and osteoporosis: Summary.

AHRQ Evidence Report Summaries. Rockville (MD): Agency for Healthcare Research and Quality (US);
 2004.

529 29. Kelley DS, Taylor PC, Nelson GJ, Mackey BE. Arachidonic acid supplementation enhances
530 synthesis of eicosanoids without suppressing immune functions in young healthy men. *Lipids* 1998;
531 33: 125-30.

53230.Thies F, Miles EA, Nebe-von-Caron G, et al. Influence of dietary supplementation with long-533chain n- 3 or n- 6 polyunsaturated fatty acids on blood inflammatory cell populations and functions534and on plasma soluble adhesion molecules in healthy adults. Lipids 2001; **36**: 1183-93.

S31. Kakutani S, Ishikura Y, Tateishi N, et al. Supplementation of arachidonic acid-enriched oil
increases arachidonic acid contents in plasma phospholipids, but does not increase their metabolites
and clinical parameters in Japanese healthy elderly individuals: a randomized controlled study. *Lipids in Health and Disease* 2011; **10**: 1-12.

Shen S, Gong C, Jin K, Zhou L, Xiao Y, Ma L. Omega-3 Fatty Acid Supplementation and
Coronary Heart Disease Risks: A Meta-Analysis of Randomized Controlled Clinical Trials. *Front Nutr*2022; **9**: 809311.

54233.Gracious BL, Chirieac MC, Costescu S, Finucane TL, Youngstrom EA, Hibbeln JR. Randomized,543placebo-controlled trial of flax oil in pediatric bipolar disorder. *Bipolar Disorders* 2010; **12**: 142-54.

54434.Sarris J, Mischoulon D, Schweitzer I. Omega-3 for bipolar disorder: meta-analyses of use in545mania and bipolar depression. J Clin Psychiatry 2012; 73: 81-6.

54635.Bazinet RP, Layé S. Polyunsaturated fatty acids and their metabolites in brain function and547disease. Nature Reviews Neuroscience 2014; 15: 771-85.

548 36. Spiller GA. Handbook of Lipids in Human Nutrition. Boca Raton (FL): CRC press; 1995.

549 37. Wei Y, Meng Y, Li N, Wang Q, Chen L. The effects of low-ratio n-6/n-3 PUFA on biomarkers of 550 inflammation: a systematic review and meta-analysis. *Food Funct* 2021; **12**: 30-40.

55138.Innes JK, Calder PC. Omega-6 fatty acids and inflammation. Prostaglandins, Leukotrienes and552Essential Fatty Acids 2018; 132: 41-8.

553 39. Ferrucci L, Cherubini A, Bandinelli S, et al. Relationship of plasma polyunsaturated fatty acids
554 to circulating inflammatory markers. *The Journal of Clinical Endocrinology & Metabolism* 2006; **91**:
555 439-46.

Sanderson E, Glymour MM, Holmes MV, et al. Mendelian randomization. *Nature Reviews Methods Primers* 2022; 2: 1-21.

558 41. Würtz P, Kangas AJ, Soininen P, Lawlor DA, Davey Smith G, Ala-Korpela M. Quantitative 559 Serum Nuclear Magnetic Resonance Metabolomics in Large-Scale Epidemiology: A Primer on -Omic 560 Technologies. American journal of epidemiology 2017; 186: 1084-96. 561 42. Soininen P, Kangas AJ, Würtz P, Suna T, Ala-Korpela M. Quantitative serum nuclear magnetic 562 resonance metabolomics in cardiovascular epidemiology and genetics. Circulation: cardiovascular 563 genetics 2015; 8: 192-206. Borges MC, Haycock PC, Zheng J, et al. Role of circulating polyunsaturated fatty acids on 564 43. 565 cardiovascular diseases risk: analysis using Mendelian randomization and fatty acid genetic 566 association data from over 114,000 UK Biobank participants. BMC Medicine 2022; 20. 567 44. Clayton GL, Borges MC, Lawlor DA. From menarche to menopause: the impact of 568 reproductive factors on the metabolic profile of over 65,000 women. medRxiv 2022: 569 https://doi.org/10.1101/2022.04.17.22273947 570 45. Ligthart S, Vaez A, Võsa U, et al. Genome analyses of> 200,000 individuals identify 58 loci for 571 chronic inflammation and highlight pathways that link inflammation and complex disorders. The American Journal of Human Genetics 2018; 103: 691-706. 572 573 Ahluwalia TS, Prins BP, Abdollahi M, et al. Genome-wide association study of circulating 46. 574 interleukin 6 levels identifies novel loci. Hum Mol Genet 2021; 30: 393-409. 575 47. Mounier N. Bias correction for inverse variance weighting Mendelian randomization. Genetic 576 Epidemiology 2023; 47: 314-31. 577 48. Foley CN, Mason AM, Kirk PDW, Burgess S. MR-Clust: clustering of genetic variants in 578 Mendelian randomization with similar causal estimates. Bioinformatics 2020; 37: 531-41. 579 Haycock PC, Borges MC, Burrows K, et al. The association between genetically elevated 49. 580 polyunsaturated fatty acids and risk of cancer. EBioMedicine 2023; 91: 104510. 581 Simopoulos AP, Cleland LGCE. Omega-6/omega-3 essential fatty acid ratio: The Scientific 50. 582 Evidence. Scandinavian Journal of Nutrition 2004; 48: 49-50. 583 Wei Y, Meng Y, Li N, Wang Q, Chen L. The effects of low-ratio n-6/n-3 PUFA on biomarkers of 51. 584 inflammation: a systematic review and meta-analysis. Food & Function 2021; 12: 30-40. 585 52. Chen Y, Lu T, Pettersson-Kymmer U, et al. Genomic atlas of the plasma metabolome 586 prioritizes metabolites implicated in human diseases. Nature Genetics 2023; 55: 44-53. 587 Simopoulos AP. Omega-3 fatty acids in inflammation and autoimmune diseases. J Am Coll 53. 588 Nutr 2002; 21: 495-505. 589 54. Bouzan C, Cohen JT, Connor WE, et al. A quantitative analysis of fish consumption and stroke 590 risk. Am J Prev Med 2005; 29: 347-52. 591 55. Siriwardhana N, Kalupahana NS, Moustaid-Moussa N. Health benefits of n-3 polyunsaturated 592 fatty acids: eicosapentaenoic acid and docosahexaenoic acid. Adv Food Nutr Res 2012; 65: 211-22. 593 56. Boyd A, Golding J, Macleod J, et al. Cohort Profile: the 'children of the 90s'--the index 594 offspring of the Avon Longitudinal Study of Parents and Children. Int J Epidemiol 2013; 42: 111-27. 57. 595 Fraser A, Macdonald-Wallis C, Tilling K, et al. Cohort Profile: the Avon Longitudinal Study of 596 Parents and Children: ALSPAC mothers cohort. Int J Epidemiol 2013; 42: 97-110. 597 58. Northstone K, Lewcock M, Groom A, et al. The Avon Longitudinal Study of Parents and 598 Children (ALSPAC): an update on the enrolled sample of index children in 2019. Wellcome Open Res 599 2019; **4**: 51. 600 59. Soininen P, Kangas AJ, Würtz P, et al. High-throughput serum NMR metabonomics for cost-601 effective holistic studies on systemic metabolism. Analyst 2009; 134: 1781-5. 602 Soininen P, Kangas AJ, Wurtz P, et al. High-throughput serum NMR metabonomics for cost-60. 603 effective holistic studies on systemic metabolism. Analyst 2009; 134: 1781-5. 604 61. Inouye M, Kettunen J, Soininen P, et al. Metabonomic, transcriptomic, and genomic variation 605 of a population cohort. Mol Syst Biol 2010; 6: 441. 606 62. Goulding N, Goudswaard L, Hughes D, et al. Inflammation proteomics datasets in the ALSPAC 607 cohort [version 1; peer review: 1 approved, 1 approved with reservations]. Wellcome Open Research 608 2022; **7**.

- 609 63. Lawlor DA, Harbord RM, Sterne JA, Timpson N, Davey Smith G. Mendelian randomization: 610 using genes as instruments for making causal inferences in epidemiology. *Statistics in Medicine*
- 611 2008; **27**: 1133-63.
- 612 64. Crick D, Sanderson E, Jones H, et al. Glycoprotein Acetyls and Depression: testing for
- directionality and potential causality using longitudinal data and Mendelian randomization analyses.medRxiv; 2022.
- 615 65. Sanderson E, Davey Smith G, Windmeijer F, Bowden J. An examination of multivariable
- 616 Mendelian randomization in the single-sample and two-sample summary data settings. International
- 617 Journal of Epidemiology 2019; **48**: 713-27.
- 618

619

620

621 Acknowledgements

- This work was carried out using the computational facilities of the Advanced Computing
 Research Centre, University of Bristol http://www.bristol.ac.uk/acrc/.
- 624 We are extremely grateful to all the families who took part in this study, the midwives for
- their help in recruiting them, and the whole ALSPAC team, which includes interviewers,
- 626 computer and laboratory technicians, clerical workers, research scientists, volunteers,627 managers, receptionists, and nurses.

628

629 Contributions

- 630 Daisy C.P. Crick: Conceptualization, Methodology, Investigation, Writing original draft,
- 631 Writing review & editing. Hannah Jones: Writing Conceptualizaion, Supervision,
- 632 Methodology, review & editing. Sarah Halligan: Supervision, Writing review & editing.
- 633 **Golam M. Khandaker:** Conceptualizaion, Methodology, Supervision, Writing review &
- 634 editing. George Davey Smith: Methodology, Writing review & editing.
- 635 Correspondence to Daisy Crick

636

637 Competing interests

- 638
- Authors declare no relevant potential conflict of interest related to the material presentedin the article.

641

642 Data availability

- Data needed to evaluate the conclusions presented in this paper are provided in the
- 644 manuscript and/or the supplementary material. Additionaly ALSPAC data can be requested
- 645 from the ALSPAC executive committee and reasonable requests from bona fide researchers.
- 646 GWAS data is publicly available using the OpenGWAS website (https://gwas.mrcieu.ac.uk)

648 **Code availability**

649 Code for data management and statistical analysis has been made available in <u>daisycrick</u>

650 (github.com).

651

- 653 Funding
- The UK Medical Research Council and Wellcome (Grant ref.: 217065/Z/19/Z) and
- the University of Bristol provide core support for ALSPAC. This publication is the work of the
- authors and DC will serve as guarantor for the contents of this paper. A comprehensive list
- 657 of grants funding is available on the ALSPAC website
- 658 (http://www.bristol.ac.uk/alspac/external/documents/grant-acknowledgements.pdf); This
- 659 research was specifically funded by Wellcome Trust and MRC (core) (Grant
- ref.: 76467/Z/05/Z), MRC (Grant ref.: MR/L022206/1) and Wellcome Trust (Grant
- 661 ref.: 8426812/Z/07/Z).
- 662 This work was supported in part by the GW4 BIOMED DTP (D.C., MR/N0137941/), awarded
- to the Universities of Bath, Bristol, Cardiff and Exeter from the Medical Research Council(MRC)/UKRI.
- GDS, GMK and HJ work within the MRC Integrative Epidemiology Unit at the University of
- Bristol, which is supported by the Medical Research Council (MC_UU_00011/1).
- 667 GMK acknowledges funding support from the Wellcome Trust (grant no: 201486/Z/16/Z and
- 668 201486/B/16/Z), the UK Medical Research Council (grant no: MC_UU_00032/06;
- 669 MR/W014416/1; and MR/S037675/1), and the UK National Institute of Health Research
- 670 Bristol Biomedical Research Centre (grant no: NIHR 203315).
- 671 HJ is supported by the NIHR Biomedical Research Centre at University Hospitals Bristol and
- 672 Weston NHS Foundation Trust and the University of Bristol. The views expressed are those
- 673 of the author(s) and not necessarily those of the NIHR or the Department of Health and 674 Social Care.
- 675 676
- 677
- 678
- 070
- 679
- 680
- 681
- 682
- 683
- 684

686 Tables

		Median (IQR)	Range
	GlycA (mmol/L)	1.22 (1.12-1.34)	0.84-2.25
	CRP (mmol/l)	0.87 (0.39-2.29)	0.1-70.05
600	IL-6 (NPX log2) DHA LA Total n-3 PUFAs Total n-6 PUFAs	3.32 (2.96-3.85) 0.11 (0.09-0.13) 2.31 (1.98-2.68) 0.29 (0.24-0.34) 2.85 (2.48-3.28)	1.82-9.86 0.04-0.32 0.89-4.91 0.07-0.80 1.23-5.82
688			
689			
690			
691			
692			
693			
694			
695			
696			
697			
698			
699			
700			
701			
702			
703			
704			
705			
706			
707			
708			



			4		
	Association between DNA and biomarkers of inflamamtion			Beta 95% Cl	
				-0.176 (-0.221, -0.131)	
				0.280 (0.239, 0.322)	
				0.121 (0.075, 0.166)	
				Beta 95% Cl	
	Association between LA and biomarkers of inflamamtion			.0 110 (-0 157 -0 062)	
				0.432 (0.392 0.472)	
				0.432 (0.352, 0.472)	
				0.122 (0.074, 0.189)	
				Beta 95% CI	
CPD	Association between Total Omega-3 and blomarkers of inflamantion				
 CRP GlycA 				-0.185 (-0.231, -0.139)	
12.0				0.271 (0.228, 0.313)	
				0.043 (-0.004, 0.089)	
				Beta 95% Cl	
	Association between Total Omega-5 and biomarkers of inflamamtion			-0.089 (-0.136, -0.042)	
			-	0.469 (0.430, 0.508)	
1				0.176 (0.130, 0.223)	
			1 1 1	Beta 95% Cl	
	Association between Total Omega-9:0mega-3 and biomarkers of inflamamtion			0.007 (0.1600.050)	
				0.207 (0.102, 0.202)	
				0.172 (0.129, 0.215)	
				0.174 (0.129, 0.220)	
		0	.0 0.4 1 unit change in bion	arker per unit change in PUFA (95% CI)	Z
	for females only				

Figure 2: Association between fatty acids and inflammatory biomarkers using cohort data after adjusting estimates for household social class, maternal highest education qualification, maternal and paternal smoking status during pregnancy, offspring sex and age and status at 24 year clinic



Figure 3: Association between fatty acids and inflammatory biomarkers stratified by sex using cohort data after adjusting estimates for household social class, maternal highest education qualification, maternal and paternal smoking status during pregnancy, offspring sex and age and status at 24 year clinic



Figure 4: Univariable causal effect of fatty acids on Inflammation



Figure 5: Multivariable Mendelian randomization analysis of direct effect of Omega-3 and Omega-6 on Inflammation